| SKIP000379 | |
| SKIP ID | SKIP000379 |
| Organism(En) | - |
| Organism(Ja) | - |
| Cell Type(En) | - |
| Cell Type(Ja) | - |
| Cell Tissue(En) | - |
| Cell Tissue(Ja) | - |
| Cell Origin | Diseased |
| Cell Name 1(En) | HPS0130 |
| Cell Name 1(Ja) | HPS0130 |
| Cell Name 2(En) | - |
| Cell Name 2(Ja) | - |
| Disease Name 1(Ja) | 孤発性筋萎縮性側索硬化症 |
| ICD Code 1 | G122 |
| Disease Name 1(En) | Amyotrophic lateral sclerosis, Sporadic type |
| OMIM1 | - |
| Disease Name 2(Ja) | - |
| ICD Code 2 | - |
| Disease Name 2(En) | - |
| OMIM 2 | - |
| Disease Name 3(Ja) | - |
| ICD Code 3 | - |
| Disease Name 3(En) | - |
| OMIM 3 | - |
| Age | - |
| Age Range | -- |
| Sex | -- |
| Race(En) | - |
| Race(Ja) | - |
| Genetic Diagnosis | No |
| Not Detected | No |
| Description(En) | Disease specific iPS cell line derived from a patient : Amyotrophic lateral sclerosis, Sporadic type (classical, with UMN). HPS0129 is derived from the same patient. Service condition: 1) The guideline must be observed when using SeV-iPS cells. 2) In relation to the for-profit organizations, please access to the following URL and consult 'iPS Academia Japan, Inc.' (http://ips-cell.net/e/index.php) prior to the utilization of iPS cells. 3) The RECIPIENT of BIOLOGICAL RESOURCE shall obtain a prior written consent on use of it from the APPROVER. 4) This cell line should be used as a collaboration work with the depositor for two years after (February, 2015) disclosure of this cell line.5) The RECIPIENT of BIOLOGICAL RESOURCE shall obtain a prior written consent on use of it from the DEPOSITOR. Contact Us : cellips@brc.riken.jp |
| Description(Ja) | 疾患特異的iPS細胞株。孤発性筋萎縮性側索硬化症 (classical, with UMN)患者由来。使用条件：1) ディナベック株式会社とBRCとの「センダイウイルスベクタートランスファーライセンス学術研究向け覚書」 を確認すること。2) 非営利機関以外の利用者は事前にiPSアカデミアジャパン株式会社（http://ips-cell.net/j/index.php）から確認書を得ること。3) 承諾者から承諾を得ること。4) 公開から2年間 (2015年2月まで) は共同研究とすること。5) 寄託者の承諾等の特殊な手続きが必要。先ずは、理研細胞バンクにお問い合わせください（cellips@brc.riken.jp)。 |
| Cell Morphology | human ES-like |
| Grade | Research Grade |
| Vector | Sendai virus |
| Transgene | SeV18+HS-OCT3/4/TS Delta F, SeV18+HS-SOX2/TS Delta F, SeV18+HS-KLF4/TS Delta F, SeV18(HNL)c-MYCQC/TS Delta F |
| Adhesiveness | - |
| Feeder | Yes |
| Feeder Cell | MEF (X-rays:5000R or MMC) 3-5x10^(5) cells/60mm dish |
| Medium | DMEM/HamF12(2mM L-Glutamine)+20%KSR+0.1mM NEAA+0.1mM 2-Mercaptoethanol+5ng/ml human bFGF |
| Genome Editing | - |
| CO2 | - |
| Mycoplasma | - |
| Detection of Contaminants Mycoplasma | - |
| Pluripotent Markers | - |
| Pluripotent Markers Assay | - |
| in vitro Differentiation | - |
| in vitro Differentiation Assay | - |
| in vivo Differentiation | - |
| in vivo Differentiation Assay | - |
| Other 1 Assay | - |
| Other 1 Assay Method | - |
| Other 2 Assay | - |
| Other 2 Assay Method | - |
| Other 3 Assay | - |
| Other 3 Assay Method | - |
| Karyotype | - |
| Karyotype Assay | - |
| Remaining Vector Detection | - |
| Remaining Vector Detection Assay | - |
| STR | - |
| HLA | - |
| Stem Cell Transcriptome analysis | - |
| Stem Cell Transcriptome analysis Assay | - |
| Author Name(En) | Apply to RIKEN |
| Author Name(Ja) | 理研に問い合わせ |
| Author Organization(En) | Apply to RIKEN |
| Author Organization(Ja) | 理研に問い合わせ |
| Author Contact Email | - |
| PI Organization(En) | RikenBRC |
| PI Organization(Ja) | 理研BRC |
| PI Name(En) | RikenBRC |
| PI Name(Ja) | 理研BRC |
| PI Contact Email | - |
| Availability | Available |
| Provider Organization(En) | RikenBRC |
| Provider Organization(Ja) | 理研BRC |
| Provider Email | cellips[at]brc[dot]riken[dot]jp |
| Provider URL | http://www2.brc.riken.jp/lab/cell/detail.cgi?cell_no=HPS0130&type=1 |
| Ethical Statement(En) | - |
| Ethical Statement(Ja) | - |
| Terms of Use(En) | - |
| Terms of Use(Ja) | - |
| PubMed ID | - |
| DOI | - |
| Title | - |
| Authors | - |
| Journal | - |
| Year | - |
| Volume | - |
| Issue | - |
| Pages | - |
| URL | - |
| Free input | - |
| Note | - |